Acorda (ACOR) is one of the more interesting biotechnology companies under our coverage. The company s key pipeline drug, Fampridine-SR, is currently under U.S. FDA review with a decision expected in late October 2009.
Outside the U.S., Acorda has partnered with Biogen Idec under very favorable terms. Fampridine-SR has blockbuster potential worldwide in our view. Plus, the company is extremely well-capitalized with over $325 million in cash and management has commercial experience with currently approved product Zanaflex.
These are among the best fundamentals in all of biotech. We reiterate our positive rating on the stock.Zacks Investment Research
